TEVA Pharmaceutical Industries Ltd (TEVA)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: Israel
Exchange: NYSE
Market cap: $137.50B
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Latest financial period: June 30, 2026
Filed with the SEC: July 29, 2026
Estimated earnings date: November 4, 2026
Profit #1039 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 28.5% | 33.7% | 29.7% | 25.2% |
Growth #815 of 1484 companies
Payout #1117 of 1484 companies
Safety #1253 of 1484 companies
Price #1276 of 1484 companies
